Skip to content
Market

New Obesity Drugs 2026: The Muscle-Saving UCN2 Peptide

Genentech's $2.3B Hanmi deal for HM17321 — a UCN2 peptide that burns fat while preserving muscle — signals the next wave of obesity drugs beyond GLP-1.

By PeptidesBeat Staff

Last reviewed

On August 24, 2026, Genentech — Roche’s U.S. subsidiary — licensed HM17321, a long-acting UCN2 peptide analog, from South Korea’s Hanmi Pharm in a deal worth up to $2.3 billion. It is the clearest signal yet that new obesity drugs 2026 are competing on body composition, not just weight. HM17321 is a non-incretin obesity candidate designed to selectively burn fat while preserving lean muscle — a mechanism distinct from the GLP-1 appetite-suppression class. For the full news facts, see our news coverage of the Genentech–Hanmi deal; this post is the pipeline analysis.

Yes. Weight-loss peptides that preserve muscle are in active development, led by UCN2 analogs such as Hanmi’s HM17321, which Genentech licensed for up to $2.3 billion. UCN2 activates CRF2 receptors to burn fat while sparing lean mass — unlike GLP-1 drugs, where 25–39% of weight lost can be muscle. None are FDA-approved yet.

What comes after GLP-1?

The next wave of obesity drugs targets body composition, not just appetite: UCN2/CRF2 peptides like HM17321, myostatin inhibitors such as bimagrumab, and amylin analogs like petrelintide aim to burn fat while preserving muscle. Most are in Phase 1–2 trials, so first approvals are still several years away.

The next wave is about body composition, not just appetite

GLP-1 drugs like Wegovy and Zepbound work through the incretin system — gut and brain receptors that suppress appetite. They are effective: clinical trials show 15–25% weight loss over 12–24 months. But the class has a documented blind spot. Published data cited in TechTimes’ coverage estimate that lean body mass accounts for roughly 25–39% of total weight lost on GLP-1 therapies — about 25% with tirzepatide and up to 39% with semaglutide. The next generation of obesity drugs is being built to fix exactly that, and how today’s oral GLP-1 options compare shows how fast the incretin side of the market is moving in parallel.

Why muscle preservation is the GLP-1 blind spot

The clinical significance of that lean-mass loss is actively debated. At the ADA 2026 Scientific Sessions, Dr. Samuel Klein of Washington University argued the loss is proportional to total weight loss and not linked to frailty, while Dr. Eric Ravussin of Louisiana State University countered that older patients with low muscle reserves face real exposure. The stakes are concrete: roughly 40% of GLP-1 users are over 60, a population with lower baseline muscle mass and higher frailty risk, and published data indicate up to two-thirds of patients discontinue GLP-1 therapy within a year — with weight regain that often includes the muscle that was lost. A drug that actively maintains or rebuilds muscle would change the risk calculus of that stop-start pattern.

Non-incretin obesity drugs: the landscape

“Non-incretin” is the label for mechanisms outside the GLP-1/GIP hormone family. HM17321 is one; myostatin inhibitors like emugrobart (formerly bimagrumab) and amylin analogs like petrelintide are others. The shared ambition is muscle-sparing fat loss — a metabolic outcome rather than a purely anorectic one. That distinction matters because what the evidence says about GLP-1 and body composition is precisely what the next wave is trying to outperform.

What is the UCN2 peptide?

UCN2 (urocortin-2) is a signaling peptide in the corticotropin-releasing factor family that activates CRF2 receptors in skeletal muscle and fat tissue. UCN2 analogs are being developed as obesity treatments because they can increase muscle mass while reducing fat — a mechanism distinct from GLP-1 appetite suppression.

Mechanism: CRF2 receptors, mTOR, fat breakdown

UCN2 binds corticotropin-releasing factor type 2 (CRF2) receptors, which are found in the central nervous system and in skeletal muscle; activating CRF2 in muscle tissue is intended to increase muscle mass and reduce fat, according to MedCity News. As our news coverage details, activation triggers the mTOR protein-synthesis pathway — a primary switch for muscle growth — while simultaneously inducing fat breakdown in adipose tissue and suppressing fat storage. Because HM17321 is a peptide, it can be delivered by subcutaneous injection, the same route as GLP-1 drugs, and Hanmi says the compound may have future potential in fixed-dose combination products alongside incretin-based treatments, per the company’s announcement.

UCN2 vs GLP-1: two different levers

GLP-1 drugs suppress appetite through incretin receptors in the gut and brain. UCN2 analogs target tissue-level partitioning instead: more muscle, less fat, at the same time. Wegovy targets GLP-1; Zepbound targets GLP-1 and GIP. Neither directly signals skeletal muscle the way UCN2 does. The two mechanisms are complementary in principle — Hanmi’s preclinical work showed HM17321 improves weight reduction both as a monotherapy and in combination with GLP-1-based therapies.

Urocortin-2’s history: heart failure to obesity

UCN2 is not new to drug developers. It is a signaling protein that is elevated in people with chronic heart failure, and the mechanism was explored by Eli Lilly in a heart-failure drug that was scrapped in 2019, Fierce Biotech notes. That history is the safety question to watch: a peptide that activates CRF2 receptors systemically will need to show its muscle-sparing effects come without cardiovascular signals.

The deal: Genentech pays $2.3B for HM17321

Deal terms

Hanmi Pharm announced on August 24, 2026 an exclusive license with Genentech to develop, make, and sell HM17321 worldwide except South Korea, which Hanmi retains. Genentech pays $190 million upfront, plus development, regulatory, and commercial milestone payments that bring the potential total to approximately $2.3 billion, with tiered royalties on future product sales, per Hanmi’s release, PharmaPhorum, and PharmExec. Yonhap frames the deal at 3.2 trillion won; Edaily at approximately 3.5 trillion won — rounding variance on the same agreement. Note that Fierce headlines a “$2.5B pact” by counting the milestones on top of the upfront; the primary source and most outlets put the total at $2.3B including the upfront.

Where it stands clinically

The U.S. FDA cleared Hanmi’s investigational new drug application in November 2025. An ongoing Phase 1 trial is evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers and people with obesity. Hanmi will complete Phase 1, after which Genentech takes over development starting with Phase 2. No efficacy or safety data have been published yet — the deal is a bet on a mechanism, not on readouts.

Preclinical signals

In preclinical studies, HM17321 showed both quantitative and qualitative improvements in weight reduction when used as a monotherapy and in combination with GLP-1-based therapies, per Hanmi — including a head-to-head study against Wegovy in monkeys, which BioPharma Dive says was run to demonstrate potential human translation. The peptide format also opens fixed-dose combination potential with incretin-based treatments.

Are there weight-loss peptides that preserve muscle?

Yes — and the pipeline extends well beyond UCN2.

The muscle-sparing pipeline: Gubra, emugrobart, petrelintide

Hanmi is not alone. Denmark’s Gubra initiated a Phase 1/2a study of its own UCN2 shot, GUB-UCN2, in obesity in July 2026 — roughly eight months after Hanmi’s IND clearance, giving the Hanmi–Genentech program a head start. Roche itself holds emugrobart, an anti-myostatin antibody in Phase 2 with Mounjaro, and Zealand Pharma’s petrelintide, an amylin analog licensed for $1.65 billion upfront, MedCity News reports. For a related mechanism outside the clinic, TOFA, another muscle-preserving fat-loss compound in the news, shows the breadth of the fat-loss-without-muscle-loss research agenda.

What this means for GLP-1 users

For people currently on GLP-1 therapy, the practical question is whether future options can keep the weight off without the lean-mass toll — and whether combinations (a UCN2 analog alongside an incretin) can beat either alone. That answer is years away. The near-term lesson is about expectations: muscle loss on GLP-1 is proportional to total weight loss, its clinical significance is genuinely contested, and no muscle-preserving obesity peptide is approved for human use yet.

When will a muscle-preserving obesity peptide reach patients?

Timeline reality

HM17321 is in Phase 1 now. Genentech takes over at Phase 2, and the standard route from there runs through Phase 3, regulatory submission, and review — the 2026 FDA peptide regulatory timeline shows how long even fast-track programs take. Realistic read: several years, even if early data are clean.

What to watch

Three things. First, the first Phase 1 safety and efficacy readout for HM17321 — the mechanism’s human proof. Second, how the $2.3B cap reconciles with Fierce’s $2.5B framing as milestones get defined. Third, how South Korea commercialization rights play out, since Hanmi retains its home market. Gubra’s Phase 1/2a is also worth watching: it will be the first independent UCN2 readout in obesity.

What peptidesbeat readers should know

UCN2 is not a buyable peptide

HM17321 is an investigational drug, not a consumer product. There is no approved, regulated UCN2 peptide; nothing sold as “UCN2” online is this compound, and unregulated purchases carry real risks. It also will not be a compounding opportunity: the 2026 FDA rules that reshaped the GLP-1 compounding landscape apply the same standards to any future peptide approval. This is the pattern we’ve tracked whenever peptide hype outpaces clinical evidence: a promising mechanism gets headlines years before patients get access. Treat this deal as a pipeline signal — not a product.

FAQ

What is the UCN2 peptide?

UCN2 (urocortin-2) is a signaling peptide in the corticotropin-releasing factor family that activates CRF2 receptors in skeletal muscle and fat tissue. UCN2 analogs are being developed as obesity treatments because they can increase muscle mass while reducing fat — a mechanism distinct from GLP-1 appetite suppression.

What comes after GLP-1?

The next wave of obesity drugs targets body composition, not just appetite: UCN2/CRF2 peptides like HM17321, myostatin inhibitors such as bimagrumab, and amylin analogs like petrelintide aim to burn fat while preserving muscle. Most are in Phase 1–2 trials, so first approvals are still several years away.

Are there weight-loss peptides that preserve muscle?

Yes. Weight-loss peptides that preserve muscle are in active development, led by UCN2 analogs such as Hanmi’s HM17321, which Genentech licensed for up to $2.3 billion. UCN2 activates CRF2 receptors to burn fat while sparing lean mass — unlike GLP-1 drugs, where 25–39% of weight lost can be muscle. None are FDA-approved yet.

How much muscle do people lose on GLP-1 drugs?

Lean body mass accounts for roughly 25–39% of total weight lost on GLP-1 therapies — about 25% with tirzepatide and up to 39% with semaglutide, per published data cited by TechTimes. The clinical significance is debated; at ADA 2026, Klein and Ravussin disagreed on whether the loss matters for older patients.

When will HM17321 be available?

Phase 1 is ongoing in healthy volunteers and people with obesity. Hanmi completes it, then Genentech takes over from Phase 2. No efficacy data are published yet, and approval is realistically several years away.

Sources

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.

Educational content, not medical advice. © 2026 PeptidesBeat.